CDMOs address the unique challenges of liquid and lyophilized forms as well as preparing for the large capacity needed for COVID-19 vaccines.
Cell-culture optimization may see benefits from a synthetic biology-based approach that improves product titer, quality, and time.
Establishing an automated inline dilution system can potentially ease bottlenecking delays resulting from higher upstream yields.
Viral clearance processes and guidance must evolve along with newer biotherapeutic modalities.